Short-Course Breast Radiation Reduces Treatment Burden
Quick Facts
Why Are Breast Radiation Courses Becoming Shorter?
Radiation therapy after breast-conserving surgery lowers the risk of cancer returning in the treated breast. Traditionally, treatment was delivered in small daily doses over several weeks, but radiobiology research showed that breast cancer can respond well to moderately larger doses per session, allowing the total course to be shortened.
The randomized FAST-Forward trial found that a regimen of 26 Gy delivered in five fractions over one week was non-inferior to 40 Gy in 15 fractions over three weeks for local tumor control at five years. The trial also assessed effects on healthy breast tissue, helping clinicians balance convenience against the possibility of late adverse effects.
How Did the Pandemic Change Breast Cancer Radiation Therapy?
During the COVID-19 pandemic, oncology services sought to reduce repeated hospital attendance while preserving effective cancer care. Short-course radiation offered a practical way to decrease potential infection exposure, conserve clinical capacity and ease transportation demands for patients.
Research reported by Medical Xpress indicates that this shift persisted beyond the pandemic and was associated with lower treatment burden and healthcare spending. The change illustrates how an emergency can accelerate implementation of an approach already supported by clinical evidence, although observational adoption data cannot by itself establish that every patient should receive the shortest regimen.
Who May Be Eligible for Five-Day Breast Radiation?
Five-fraction whole-breast radiation is primarily supported by evidence in people treated for early-stage disease. Decisions may also consider lymph-node involvement, whether regional lymph nodes require radiation, previous radiation exposure, breast reconstruction, connective-tissue disorders and the ability to meet dose constraints for the heart, lungs and other healthy tissues.
Shorter treatment does not mean weaker treatment: each session delivers a larger dose, and careful planning remains essential. Patients should ask whether the proposed schedule is supported for their clinical situation, what short- and long-term adverse effects are possible, and whether techniques such as deep-inspiration breath hold could reduce cardiac exposure when treating the left breast.
Frequently Asked Questions
For appropriately selected patients with early-stage breast cancer, the FAST-Forward randomized trial found that 26 Gy in five treatments was non-inferior to 40 Gy in 15 treatments for local cancer control at five years. Individual recommendations still depend on the treatment area and patient-specific factors.
Short-course treatment uses a larger dose at each visit, but established regimens are designed to keep effects on healthy tissue within acceptable limits. Possible effects include fatigue, skin irritation, breast swelling and later changes in breast appearance or firmness; personal risks should be reviewed during radiation planning.
No. Evidence is strongest in defined early-stage settings, and some patients requiring complex regional lymph-node treatment, re-irradiation or specialized postoperative care may need another schedule.
References
- Medical Xpress. COVID-19 pandemic accelerated adoption of shorter, lower-burden (lower cost) breast radiation therapy. September 2026.
- Brunt AM, Haviland JS, Wheatley DA, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): five-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. The Lancet. 2020;395:1613-1626.
- Smith BD, Bellon JR, Blitzblau R, et al. Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology evidence-based guideline. Practical Radiation Oncology. 2018;8:145-152.